RxDoctor Payments Data

Rhazes Khodadad, MD

Internal Medicine · Cincinnati, OHNPI 1558363960

Payments from drug & device makers

$1,324in general payments, 2019–2025

Across 91 payments — averaging $14.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$458
  • Abbott$210
  • Lilly USA, LLC$143
  • Pfizer$115
  • Johnson & Johnson$69
  • AbbVie$60
  • plus $270 from 12 others

What the payments were for

  • Food & beverage$1,30098%
  • Education$232%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,324 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$126,837
Medicare patients
324
Services billed
1,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide151$173,055
EliquisApixaban271$102,687
XareltoRivaroxaban153$86,883
TrulicityDulaglutide42$53,694
JardianceEmpagliflozin45$44,182
EntrestoSacubitril/Valsartan48$25,010
FarxigaDapagliflozin Propanediol37$23,890
MounjaroTirzepatide17$22,282
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,223
JanuviaSitagliptin Phosphate28$17,486
Sevelamer Carbonate60$13,259
Breo ElliptaFluticasone/Vilanterol29$12,077
Atorvastatin Calcium1,044$10,309
MyrbetriqMirabegron34$7,772
Memantine Hcl92$7,030

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$458$173,055151 claims
PfizerEliquis$115$102,687271 claims
Johnson & JohnsonXarelto$69$86,883153 claims
Lilly USA, LLCTrulicity, Mounjaro$143$75,97659 claims
Boehringer IngelheimJardiance, Synjardy Xr$14$48,25756 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$35$42,447111 claims
AstraZenecaFarxiga, Breztri Aerosphere$23$29,80648 claims
NovartisEntresto$15$25,01048 claims
MerckJanuvia$13$17,48628 claims
Astellas Pharma US IncMyrbetriq$39$7,77234 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Cincinnati

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →